Pliant Therapeutics (PLRX) Projected to Post Earnings on Wednesday

Key Points

• Pliant Therapeutics (PLRX) is set to announce its Q2 2025 earnings on August 6th, with analysts projecting a loss of ($0.62) per share.
• The company's shares opened at $1.46 with a market capitalization of approximately $89.63 million, showing significant price volatility over the past year.
• Institutional investors own 97.30% of Pliant Therapeutics stock, with several hedge funds increasing their stakes significantly in the first quarter of the year.

Pliant Therapeutics (NASDAQ:PLRX - Get Free Report) is anticipated to release its Q2 2025 earnings data before the market opens on Wednesday, August 6th. Analysts expect Pliant Therapeutics to post earnings of ($0.62) per share for the quarter.

Pliant Therapeutics Price Performance

PLRX stock traded up $0.12 during midday trading on Friday, reaching $1.58. 1,475,751 shares of the company's stock traded hands, compared to its average volume of 1,784,770. The business has a 50-day moving average price of $1.40 and a two-hundred day moving average price of $2.86. Pliant Therapeutics has a fifty-two week low of $1.10 and a fifty-two week high of $16.10. The company has a market capitalization of $96.99 million, a P/E ratio of -0.44 and a beta of 1.30.

Institutional Investors Weigh In On Pliant Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. increased its holdings in Pliant Therapeutics by 42.2% in the first quarter. Invesco Ltd. now owns 68,963 shares of the company's stock worth $93,000 after buying an additional 20,449 shares during the last quarter. AQR Capital Management LLC bought a new position in Pliant Therapeutics in the first quarter worth $97,000. Jane Street Group LLC raised its stake in Pliant Therapeutics by 1,270.0% during the first quarter. Jane Street Group LLC now owns 136,716 shares of the company's stock worth $185,000 after acquiring an additional 148,401 shares in the last quarter. Royal Bank of Canada raised its stake in Pliant Therapeutics by 222.4% during the first quarter. Royal Bank of Canada now owns 362,702 shares of the company's stock worth $491,000 after acquiring an additional 250,185 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Pliant Therapeutics by 6.5% in the first quarter. Goldman Sachs Group Inc. now owns 475,877 shares of the company's stock valued at $642,000 after buying an additional 29,177 shares in the last quarter. 97.30% of the stock is owned by institutional investors and hedge funds.

About Pliant Therapeutics

Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis.